תוצאות חיפוש - Birgit Bossenmaier

  • Showing 1 - 14 results of 14
Refine Results
  1. 1
    Acquired Resistance to Antibody-Drug Conjugates

    Acquired Resistance to Antibody-Drug Conjugates מאת Denis M. Collins, Birgit Bossenmaier, Gwendlyn Kollmorgen, Gerhard Niederfellner

    יצא לאור 2019
    קבל טקסט מלא קבל טקסט מלא
    Revisão
    הוספה למועדפים
    שמור ב:
  2. 2
    Protein kinase C isoforms β 1 and β 2 inhibit the tyrosine kinase activity of the insulin receptor

    Protein kinase C isoforms β 1 and β 2 inhibit the tyrosine kinase activity of the insulin receptor מאת Birgit Bossenmaier, Luitgard Mosthaf, Harald Mischak, A. Ullrich, Hans‐Ulrich Häring

    יצא לאור 1997
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  3. 3
    Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models

    Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models מאת Werner Scheuer, Thomas Friess, Helmut Burtscher, Birgit Bossenmaier, Josef Endl, Max Hasmann

    יצא לאור 2009
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  4. 4
    Differential activities of protein tyrosine phosphatases in intact cells.

    Differential activities of protein tyrosine phosphatases in intact cells. מאת Reiner Lammers, Birgit Bossenmaier, D E Cool, N. K. Tonks, Joseph Schlessinger, E H Fischer, A. Ullrich

    יצא לאור 1993
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  5. 5
    Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling.

    Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling. מאת G Kroder, Birgit Bossenmaier, Monika Kellerer, Edison Capp, B Stoyanov, A Mühlhöfer, Lucia Berti, Hiroyoshi Horikoshi, A. Ullrich, Hans-Ulrich Häring

    יצא לאור 1996
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  6. 6
    Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer

    Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer מאת Denis M. Collins, Wolfgang Jacob, Juan Miguel Cejalvo, Maurizio Ceppi, Ian James, Max Hasmann, John Crown, Andrés Cervantes, Maja Weisser, Birgit Bossenmaier

    יצא לאור 2017
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  7. 7
    Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity

    Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity מאת Yasmin Leshem, James O'Brien, Xiufen Liu, Tapan K. Bera, Masaki Terabe, Jay A. Berzofsky, Birgit Bossenmaier, Gerhard Niederfellner, Chin‐Hsien Tai, Yoram Reiter, Ira Pastan

    יצא לאור 2017
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  8. 8
    RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation

    RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation מאת Christian Mirschberger, Christian Schiller, Michael Schräml, Nikolaos Dimoudis, Thomas Friess, Christian A. Gerdes, Ulrike Reiff, Valeria Lifke, Gabriele Hoelzlwimmer, Irene Kolm, Karl‐Peter Hopfner, Gerhard Niederfellner, Birgit Bossenmaier

    יצא לאור 2013
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  9. 9
    GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior <i>In Vivo</i> Efficacy Compared with Cetuximab

    GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior <i>In Vivo</i> Efficacy Compared with Cetuximab מאת Christian A. Gerdes, Valeria Nicolini, Sylvia Herter, Erwin van Puijenbroek, Sabine M. Lang, Michaela Roemmele, Ekkehard Moessner, Olivier Freytag, Thomas Friess, Carola H. Ries, Birgit Bossenmaier, Hans Joachim Mueller, Pablo Umaña

    יצא לאור 2012
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  10. 10
    ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody<sup>89</sup>Zr-RG7116

    ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody<sup>89</sup>Zr-RG7116 מאת Anton G.T. Terwisscha van Scheltinga, Marjolijn N. Lub–de Hooge, K. Abiraj, Carolien P. Schröder, Linda Pot, Birgit Bossenmaier, Marlène Thomas, Gabriele Hölzlwimmer, Thomas Friess, Jos G.W. Kosterink, Elisabeth G.E. de Vries

    יצא לאור 2014
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  11. 11
    Characterization of a re‐engineered, mesothelin‐targeted<i>Pseudomonas</i>exotoxin fusion protein for lung cancer therapy

    Characterization of a re‐engineered, mesothelin‐targeted<i>Pseudomonas</i>exotoxin fusion protein for lung cancer therapy מאת Frieder Bauss, Martin Lechmann, Ben‐Fillippo Krippendorff, Roland F. Staack, Frank Herting, Matthias Festag, Sabine Imhof-Jung, Friederike Hesse, Marc Pompiati, Gwendlyn Kollmorgen, Rita da Silva Mateus Seidl, Birgit Bossenmaier, Wilma Lau, Christian Schantz, Jan Olaf Stracke, Ulrich Brinkmann, Masanori Onda, Ira Pastan, Klaus Bosslet, Gerhard Niederfellner

    יצא לאור 2016
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  12. 12
    The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner

    The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner מאת Janet K. Peper-Gabriel, Marina Pavlidou, Lucia Pattarini, Aizea Morales‐Kastresana, Thomas J. Jaquin, Catherine Gallou, Eva-Maria Hansbauer, Marleen Richter, Hélène Lelièvre, Alix Scholer‐Dahirel, Birgit Bossenmaier, Celine Sancerne, Matthieu Rivière, Maximilien Grandclaudon, Markus Zettl, Rachida S. Bel Aiba, Christine Rothe, Véronique Blanc, Shane A. Olwill

    יצא לאור 2022
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  13. 13
    First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

    First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors מאת Didier Meulendijks, Wolfgang Jacob, Maria Martinez‐García, Álvaro Taus, Martijn P. Lolkema, Emile E. Voest, Marlies H.G. Langenberg, Tania Fleitas, Andrés Cervantes, Maja J. De Jonge, Stefan Sleijfer, Morten Mau‐Sørensen, Marlène Thomas, Maurizio Ceppi, Georgina Meneses‐Lorente, Ian James, Céline Adessi, Francesca Michielin, K. Abiraj, Birgit Bossenmaier, Jan H.M. Schellens, Maja Weisser, Ulrik Lassen

    יצא לאור 2015
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  14. 14
    Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

    Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer מאת Denis M. Collins, Stephen F. Madden, Nicola Gaynor, Dalal AlSultan, Marion Le Gal, Alex J. Eustace, Kathy Gately, Clare Hughes, Anthony M. Davies, Thamir Mahgoub, Jo Ballot, Sinéad Toomey, Darran P. O’Connor, William M. Gallagher, Frankie A. Holmes, Virginia Espina, Lance A. Liotta, Bryan T. Hennessy, Kenneth J. O’Byrne, Max Hasmann, Birgit Bossenmaier, Norma O’Donovan, John Crown

    יצא לאור 2020
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:

כלי חיפוש: